Logo
x

Search

Subscribe Now

inflarx

InflaRx’s Gohibic (Vilobelimab) Receives the EC Approval for the Treatment of ARDS

InflaRx’s Gohibic (Vilobelimab) Receives the EC Approval for the Treatment of ARDS

  • January 17, 2025
InflaRx’s Gohibic (Vilobelimab) Gains the CHMP’s Positive Opinion for the Treatment of ARDS

InflaRx’s Gohibic (Vilobelimab) Gains the CHMP’s Positive Opinion for the Treatment of ARDS

  • November 15, 2024
InflaRx Report EMA’s Validation of MAA for Vilobelimab to Treat Critically Ill COVID-19 Patients

InflaRx Report EMA’s Validation of MAA for Vilobelimab to Treat Critically Ill COVID-19 Patients

  • August 30, 2023
InflaRx Receives the US FDA’s EUA for Gohibic (vilobelimab) to Treat COVID-19

InflaRx Receives the US FDA’s EUA for Gohibic (vilobelimab) to Treat COVID-19

  • April 5, 2023
InflaRx Reports Results of Vilobelimab in the P-III Part of P-II/III (PANAMO) Study for the Treatment of Severe COVID-19

InflaRx Reports Results of Vilobelimab in the P-III Part of P-II/III (PANAMO) Study for the Treatment of Severe COVID-19

  • April 1, 2022
PharmaShots Weekly Snapshots (May 10 - 14, 2021)

PharmaShots Weekly Snapshots (May 10 - 14, 2021)

  • May 14, 2021
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2025 PharmaShots - All Rights Reserved.